# Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran)

Lewis Au,1,2,13 Annika Fendler,1,13 Scott Shepherd,1,2 Karolina Rzeniewicz,1 Maddalena Cerrone,3 Fiona Byrne,1 Eleanor Carlyle,2 Kim Edmonds,2 Lyra Del Rosario,2 John Shon,4 Winston A Haynes,4 Barry Ward,1 Ben Shum,1,2 William Gordon,1 Camille L Gerard,1,5 Wenyi Xie,1 Nalinie Joharatnam-Hogan,2 Kate Young,2 Andrew Furness,2 Lisa Pickering,2 James Larkin,2 Ruth Harvey,6 George Kassiotis,7 Sonia Ghandi,8 Charles Swanton9 on behalf of the Crick COVID-19 Consortium, Charlotte Fribbens,10 Katalin A Wilkinson,3 Robert J Wilkinson,3,11 David K Lau,12 Naureen Starling,12 Ian Chau,12 Samra Turajlic,1,2\* on behalf of the CAPTURE Consortium

1Cancer Dynamics Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

2Skin and Renal Units, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

3Tuberculosis Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

4Serimmune, Inc., Goleta, CA, USA

5Precision Oncology Center, Lausanne University Hospital (CHUV), Switzerland

6Worldwide Influenza Centre, The Francis Crick Institute, London, NW1 1AT, UK

7Retroviral Immunology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

8Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

9Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, NW1 1AT, UK

10Acute Oncology Service, The Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK

11Department of Infectious Disease, Imperial College London, London, W12 0NN, UK

12Gastrointestinal Unit, The Royal Marsden NHS Foundation Trust, London and Surrey SM2 5PT

13Equal Contribution

**\*Corresponding author:** Samra Turajlic ([samra.turajlic@crick.ac.uk](mailto:samra.turajlic@crick.ac.uk))

# Supplementary Files

**Supplementary Figures**

**Figure S1. Gating strategy for T-cell assay**

**Diagram, engineering drawing

Description automatically generated**

**a)** CD4+ T-cell response to SEB in exemplary samples. **b)** CD8+ T-cell response to SEB in exemplary samples. **c)** Gating strategy for flow analysis of T-cell activation. PBMCs were stimulated with SEB for 24 hrs. SEB, Staphylococcal enterotoxin B

**Figure S2. Antibody response to BNT162b2 according to SERA and PIWAS**

![A picture containing graphical user interface

Description automatically generated]()

**a)**Pre- and post-vaccination antibody levels against SARS-CoV-2 antigenic motifs. **b)**PIWAS values pre- and post-vaccination against non-spike sequences of the SARS-CoV-proteome compared to patients with SARS-CoV-2 positive subjects1 (**Methods**). PIWAS, protein-based immunome wide association study; SERA, serum epitope repertoire analysis

**Supplementary Tables**

**Table S1: List of antibodies used in AIM assay**

|  |  |  |  |
| --- | --- | --- | --- |
| Antibody | Fluorochrome | Clone | Vendor |
| CD14 | V500 | M5E2 | BD |
| CD19 | V500 | HIB19 | BD |
| CD4 | BV605 | OKT4 | Biolegend |
| CD8 | BV650 | RPA-T8 | Biolegend |
| CD69 | PE-CF594 | FN50 | BD |
| OX40 | PE-Cy7 | Ber-ACT35 | Biolegend |
| CD137 | APC | 4B4-1 | Biolegend |
| CD3 | AF700 | OKT3 | Biolegend |

**Supplementary References**

1 Haynes, W. A. *et al.* High-resolution mapping and characterization of epitopes in COVID-19 patients. *medRxiv*, 2020.2011.2023.20235002, doi:10.1101/2020.11.23.20235002 (2020).